Stocktoria
PALISADE BIO, INC. PALI
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2006-12-20
PALISADE BIO, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | — | — | -4356.7% | — | — | -68764.8% | -56071.8% | -3176.7% | -5118.1% | -127027.2% |
| Net margin | — | — | -4100.0% | — | — | -76346.2% | -54252.6% | -1894.1% | -6025.4% | -129721.8% |
| FCF margin | — | — | -3712.3% | — | — | -35310.7% | — | -2959.3% | -5164.4% | -96726.6% |
| Return on assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% | -341.9% | -126.8% | -64.1% | -112.8% | -93.2% |
| Return on equity | -13.0% | -192.7% | -108.7% | -114.3% | -361.4% | 62.2% | 100.2% | -81.4% | -184.0% | -186.0% |
| Debt / equity | — | — | — | — | 0.01× | -0.07× | — | — | — | — |
| Current ratio | 28.95 | 3.24 | 5.15 | 4.89 | 4.61 | 0.11 | 4.61 | 6.19 | 8.22 | 2.85 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.